- Clinical-stage biotech Atara Biotherapeutics ( NASDAQ: ATRA ) surged ~16% as the company plans to report interim data on Tuesday from its Phase 2 EMBOLD study for ATA188, a CAR T immunotherapy for progressive multiple sclerosis.
- About ~1.2M shares have changed hands, exceeding the 65-day average of ~1.1M as Atara ( ATRA ) recorded the best intraday gain since May 2020.
- The upcoming data readout will include efficacy, safety, and biomarker data that will further guide the late-stage development of ATA188.
- Last week, Atara ( ATRA ) announced that the results from the interim analysis would be disclosed on Tuesday, a delay from the June timeline indicated with the company’s 1Q 2022 results.
- Underperforming the broader market, the company shares have dropped ~15% since the announcement, as shown in this graph.
For further details see:
Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate